Key result
Pharmacological Ras inhibition decreases early fibrotic response in obstructed kidneys by reducing Ras/Erk/Akt signaling.
Why the study?
The effect of inhibiting angiotensin II receptors or Ras activation on early renal fibrotic changes induced by unilateral ureteral obstruction was assessed to explore potential prevention strategies for renal fibrosis.
Pharmacological inhibition of Ras activation via AT1 receptor blockade or Ras prenylation inhibitors reduces early renal fibrotic changes in a murine model of obstructive nephropathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for targeting Ras or angiotensin II pathways in early renal fibrosis; leaves open whether.
Tubulointerstitial fibrosis is a major feature of chronic kidney disease. Unilateral ureteral obstruction (UUO) in rodents leads to the development of renal tubulointerstitial fibrosis consistent with histopathological changes observed in advanced chronic kidney disease in humans. The purpose of this study was to assess the effect of inhibiting angiotensin II receptors or Ras activation on early renal fibrotic changes induced by UUO. Animals either received angiotensin II or underwent UUO. UUO animals received either losartan, atorvastatin, and farnesyl transferase inhibitor (FTI) L-744,832, or chaetomellic acid A (ChA). Levels of activated Ras, phospho-ERK1/2, phospho-Akt, fibronectin, and α-smooth muscle actin were subsequently quantified in renal tissue by ELISA, Western blot, and/or immunohistochemistry. Our results demonstrate that administration of angiotensin II induces activation of the small GTPase Ras/Erk/Akt signaling system, suggesting an involvement of angiotensin II in the early obstruction-induced activation of renal Ras. Furthermore, upstream inhibition of Ras signalling by blocking either angiotensin AT1 type receptor or by inhibiting Ras prenylation (atorvastatin, FTI o ChA) reduced the activation of the Ras/Erk/Akt signaling system and decreased the early fibrotic response in the obstructed kidney. This study points out that pharmacological inhibition of Ras activation may hold promise as a future strategy in the prevention of renal fibrosis.
No takes yet. Share an insight, caveat, or question.
Rodríguez-Peña et al. (2014) studied Obstructive nephropathy. Losartan, atorvastatin, FTI L-744,832, or chaetomellic acid A vs. Untreated UUO animals was evaluated on Levels of activated Ras, phospho-ERK1/2, phospho-Akt, fibronectin, and α-smooth muscle actin. Pharmacological inhibition of Ras activation via AT1 receptor blockade or Ras prenylation inhibitors reduced Ras/Erk/Akt signaling and decreased the early fibrotic response in obstructed kidneys.
Synapse has enriched 10 related papers. Consider them for comparative context: